This site is intended for healthcare professionals
News

Data from NP30179 study of glofitamab for relapsed or refractory diffuse large B-cell lymphoma submitted to EMA.

Read time: 1 mins
Published:21st Jun 2022

Data from the NP30179 study of glofitamab have been submitted by Genentech/Roche for approval to the European Medicines Agency (EMA), and submissions to additional health authorities worldwide, including to the FDA, are planned this year.

Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab (given for a fixed amount of time, and not taken until disease progression) induces durable complete responses (CRs) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who had received a median of three prior therapies.

Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment.

Condition: Diffuse Large B Cell Lymphoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights